Home › Research › Treatments
Economic evaluation of donepezil in moderate to severe Alzheimer disease
Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Xu Y, Schwam EM, Shah S et al.. Neurology, 2004-08-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Objective To investigate the costs to society of Alzheimer disease (AD) care in a multinational, randomized, placebo-controlled trial of donepezil in patients with moderate to severe AD. Methods A total of 290 patients with AD (screening standardized Mini-Mental State Examination score 5 to 17) were randomized to receive either donepezil (n = 144; 5 mg/day for 28 days, followed by 10 mg/day as per clinician's judgment) or placebo (n = 146) for 24 weeks. The authors collected data on patient and caregiver health resource utilization prospectively using the Canadian Utilization of Services Tracking questionnaire. Costs were calculated for patients and caregivers in each group based on resource utilization multiplied by the unit prices for each resource. A cost (the average Ontario minimum wage for 1998 [Can 6.85 dollars per hour]) was assigned to unpaid time that caregivers spent assisting the patient with activities of daily living (ADL). Results Patient and caregiver demographics at baseline were similar across the two groups. After adjusting for baseline total cost per patient, the mean total societal cost per patient for the 24-week period was donepezil, Can 9,904 dollars (US 6,686 dollars) and placebo, Can 10,236 dollars (US 6,910 dollars). This net cost saving of Can 332 dollars (US 224 dollars) included the average 24-week cost of donepezil treatment. Most of the cost-saving with donepezil treatment was due to less use of residential care by patients, and caregivers spending less time assisting patients with ADL. Conclusion This cost-consequence analysis reveals economic benefits of treatment of moderate to severe AD with donepezil.
What this study adds
Evidence grade: High
This is a trial of 144 participants. In 290 patients with moderate to severe Alzheimer's disease, donepezil was associated with a net societal cost saving of Can 332 dollars over 24 weeks compared with placebo. This is an economic evaluation of costs, not evidence about treating, curing, or preventing Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Feldman, H., Gauthier, S., Hecker, J., Vellas, B., Hux, M., Xu, Y., et al. (2004). Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology. https://doi.org/10.1212/01.wnl.0000134663.79663.6e
Vancouver
Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Xu Y, et al. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology. 2004. doi:10.1212/01.wnl.0000134663.79663.6e. PMID: 15326236.
BibTeX
@article{feldman2004-15326236,
author = {Feldman, H. and Gauthier, S. and Hecker, J. and Vellas, B. and Hux, M. and Xu, Y. and Schwam, E. M. and Shah, S. and others},
title = {{Economic evaluation of donepezil in moderate to severe Alzheimer disease}},
journal = {Neurology},
year = {2004},
doi = {10.1212/01.wnl.0000134663.79663.6e},
pmid = {15326236},
url = {https://doi.org/10.1212/01.wnl.0000134663.79663.6e}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Patient and caregiver demographics at baseline were similar across the two groups.
Why it matters
In 290 patients with moderate to severe Alzheimer's disease, donepezil was associated with a net societal cost saving of Can 332 dollars over 24 weeks compared with placebo. This is an economic evaluation of costs, not evidence about treating, curing, or preventing Alzheimer's disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants144
- Evidence strengthHigh
How this study scored 66/100
Published in a leading specialty journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2004 — older than 20 years, still counted |
| Sample size | 2 / 4 | 144 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 4 / 7 | Cited 84 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.5 citations a year over 24 year(s) since 2004 |
| Impact for its field and year | 5 / 6 | Cited 26.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 1 / 4 | Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Vera Mastey: h-index 23 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | University of British Columbia Hospital: institution h-index 253 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | PubMed indexes it as a multicentre study |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 15326236) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 66 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.